![Kathryn Hayashi](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Kathryn Hayashi
Directeur Général chez
TRIUMF Innovations, Inc.
Profil
Kathryn Hayashi currently works at TRIUMF Innovations, Inc., as CEO from 2017, ARTMS, Inc., as Director from 2018, Nimbus Synergies, Inc., as Board of Director from 2017, and Centre For Commercialization of Cancer Immunotherapy, as Director.
Ms. Hayashi also formerly worked at Sitka Biopharma, Inc., as Director from 2016 to 2017, Zucara Therapeutics, Inc., as Director from 2015 to 2017, and The Centre for Drug Research & Development, as CFO from 2006 to 2017.
Ms. Hayashi received her undergraduate degree in 2000 from the University of British Columbia.
Postes actifs de Kathryn Hayashi
| Sociétés | Poste | Début |
|---|---|---|
ARTMS, Inc.
 ARTMS, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Directeur/Membre du Conseil | 28/03/2018 |
Centre For Commercialization of Cancer Immunotherapy
 Centre For Commercialization of Cancer Immunotherapy BiotechnologyHealth Technology Manufactures cell and gene products | Directeur/Membre du Conseil | - |
Nimbus Synergies, Inc.
 Nimbus Synergies, Inc. Investment ManagersFinance Nimbus Synergies invests in companies located in North America primarily in Canada and opportunistically in the United States with revenues of USD 0.5 - 2 million. The firm focuses on the health technology sector. It participates in pre-seed, seed and early stage capital requirements with an investment size of USD 0.25 - 5 million. The firm makes co-investments and also acts as a lead investor. It takes a seat on the board of directors. The firm makes follow-on investments and it does not invest in therapeutics and class III devices. | Directeur/Membre du Conseil | 01/09/2017 |
TRIUMF Innovations, Inc.
 TRIUMF Innovations, Inc. Information Technology ServicesTechnology Services Provides information technology services | Directeur Général | 01/02/2017 |
Anciens postes connus de Kathryn Hayashi
| Sociétés | Poste | Fin |
|---|---|---|
Sitka Biopharma, Inc.
 Sitka Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops novel polymer platform technology that improves drug absorption for cancer treatments | Directeur/Membre du Conseil | 01/01/2017 |
Zucara Therapeutics, Inc.
 Zucara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drug therapy for hypoglycemia in type 1 diabetes people | Directeur/Membre du Conseil | 01/01/2017 |
The Centre for Drug Research & Development
 The Centre for Drug Research & Development Miscellaneous Commercial ServicesCommercial Services Discovers, research and develops therapeutic products | Directeur Financier/CFO | 01/01/2017 |
Formation de Kathryn Hayashi
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
95
Relations au 1er degré
8
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 8 |
|---|---|
University of British Columbia
 University of British Columbia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Centre for Drug Research & Development
The Centre for Drug Research & Development Miscellaneous Commercial ServicesCommercial Services Discovers, research and develops therapeutic products | Commercial Services |
Sitka Biopharma, Inc.
Sitka Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops novel polymer platform technology that improves drug absorption for cancer treatments | Health Technology |
ARTMS, Inc.
ARTMS, Inc. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Nimbus Synergies, Inc.
Nimbus Synergies, Inc. Investment ManagersFinance Nimbus Synergies invests in companies located in North America primarily in Canada and opportunistically in the United States with revenues of USD 0.5 - 2 million. The firm focuses on the health technology sector. It participates in pre-seed, seed and early stage capital requirements with an investment size of USD 0.25 - 5 million. The firm makes co-investments and also acts as a lead investor. It takes a seat on the board of directors. The firm makes follow-on investments and it does not invest in therapeutics and class III devices. | Finance |
Zucara Therapeutics, Inc.
Zucara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures drug therapy for hypoglycemia in type 1 diabetes people | Health Technology |
TRIUMF Innovations, Inc.
TRIUMF Innovations, Inc. Information Technology ServicesTechnology Services Provides information technology services | Technology Services |
Centre For Commercialization of Cancer Immunotherapy
Centre For Commercialization of Cancer Immunotherapy BiotechnologyHealth Technology Manufactures cell and gene products | Health Technology |
